N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT01265563

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01265563
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01265563. Randomized; triple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2017-03-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Acronym
CGDN
Condition
Diabetic Nephropathy
Condition
Proteinuria
Condition
Oxidative Stress
Intervention (Drug)
N-acetylcysteine placebo and silibin placebo
Intervention (Drug)
N-acetylcysteine active and silibin placebo
Intervention (Drug)
N-acetylcysteine placebo and silibin active
Intervention (Drug)
N-acetylcysteine active and silibin active
Intervention (Drug)
N-acetylcysteine active + high-dose silibin active
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01265563
Content hash
cedd7f98fc97b1851c8829538db7b3da7c4ab2e71e715c47fe1b152bce13fe20